CelLBxHealth (CLBX) H1 2026 earnings summary

Executive summary

• Q2 2026 revenue doubled sequentially to £0.4 million, with H1 2026 revenue at £0.6 million, down from £0.8 million in H1 2025.

• Gross margin improved to 61% in H1 2026 from 59% in H1 2025.

• Operating loss for H1 2026 significantly reduced to £2.7 million from £9.7 million year-over-year.

• Restructuring led to a 61% reduction in annualised burn rate and a leaner, more commercially focused business.

• Strategic partnerships advanced with AstraZeneca, AdventHealth, QIAGEN, Roche Diagnostics, Illumina, and Myriad.

Financial highlights

• Q2 2026 revenue: £0.4 million (100% increase over Q1 2026).

• H1 2026 revenue: £0.6 million (H1 2025: £0.8 million).

• Gross profit: £0.4 million (H1 2025: £0.5 million); gross margin: 61%.

• Operating loss: £2.7 million (H1 2025: £9.7 million); loss after tax: £2.7 million (H1 2025: £9.3 million).

• Cash and cash equivalents at 30 June 2026: £2.9 million (30 June 2025: £5.3 million).

Outlook and guidance

• FY2026 revenues expected to be at least £2.1 million, representing at least 50% growth over FY2025.

• Reduced operating cost base and improved cash utilisation provide runway into Q2 2027.

• Commercial pipeline of £3.5 million supported by increased engagement from partners.

• EBITDA positive expected in 2028, contingent on further revenue growth.